SSR 125329
Alternative Names: SR 125329Latest Information Update: 23 Feb 2009
Price :
$50 *
At a glance
- Originator sanofi-aventis
- Class
- Mechanism of Action Sigma receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer; Inflammation
Most Recent Events
- 23 Feb 2009 Discontinued - Phase-I for Cancer in Europe (unspecified route)
- 01 Mar 2005 Discontinued - Phase-I for Inflammation in Europe (unspecified route)
- 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis